Michael A E, Gregory L, Piercy E C, Walker S M, Shaw R W, Cooke B A
Department of Biochemistry and Molecular Biology, Royal Free Hospital School of Medicine, University of London, United Kingdom.
Fertil Steril. 1995 Sep;64(3):590-8.
To determine the relationship of ovarian 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD) activity to the outcome of IVF-ET and to establish whether 11 beta-HSD activities vary for a given patient between consecutive treatment cycles.
Retrospective correlation analysis.
Patients were treated and ovarian 11 beta-HSD activities were measured at independent fertility and biochemistry departments, respectively.
Random series of 137 women undergoing a total of 172 treatment cycles for IVF-ET.
Subcutaneous buserelin acetate plus IM hMG and hCG for controlled ovarian hyperstimulation; blood samples were collected for plasma LH and steroid determinations.
Presence or absence of detectable ovarian 11 beta-HSD activity, oocyte fertilization rates, and the identification of clinical pregnancies.
None of the 101 cycles associated with 11 beta-HSD positive granulosa-lutein cells resulted in clinical pregnancies, whereas the pregnancy rate for the 71 patients with undetectable ovarian 11 beta-HSD activity was 63.4% per cycle. The incidence of total fertilization failure was lower and the median oocyte fertilization rate was higher in cycles characterized by 11 beta-HSD-negative cells. Plasma concentrations of LH and E2 were higher in cycles yielding 11 beta-HSD-negative cells, whereas plasma P, patient age, and the number of oocytes retrieved did not relate to ovarian 11 beta-HSD activity. For the 35 patients studied in repeat cycles, ovarian 11 beta-HSD activities did not relate to those in the initial cycles.
Ovarian 11 beta-HSD activity is associated with failure to conceive by IVF-ET. For a given patient, ovarian 11 beta-HSD activity varies between consecutive treatment cycles. Hence, ovarian 11 beta-HSD activities may predict the outcome of this assisted reproduction protocol independently in each treatment cycle.
确定卵巢11β-羟类固醇脱氢酶（11β-HSD）活性与体外受精-胚胎移植（IVF-ET）结局之间的关系，并确定11β-HSD活性在给定患者的连续治疗周期之间是否存在差异。
回顾性相关性分析。
患者分别在独立的生殖医学科和生物化学科接受治疗并检测卵巢11β-HSD活性。
随机选取137名接受IVF-ET共172个治疗周期的女性。
皮下注射醋酸布舍瑞林加肌肉注射人绝经期促性腺激素（hMG）和人绒毛膜促性腺激素（hCG）进行控制性卵巢过度刺激；采集血样检测血浆促黄体生成素（LH）和类固醇激素水平。
是否检测到卵巢11β-HSD活性、卵母细胞受精率以及临床妊娠的识别。
与11β-HSD阳性颗粒黄体细胞相关的101个周期均未获得临床妊娠，而卵巢11β-HSD活性检测不到的71名患者的妊娠率为每个周期63.4%。以11β-HSD阴性细胞为特征的周期中，完全受精失败的发生率较低，卵母细胞受精率中位数较高。产生11β-HSD阴性细胞的周期中，血浆LH和雌二醇（E2）浓度较高，而血浆孕酮（P）、患者年龄和回收的卵母细胞数量与卵巢11β-HSD活性无关。对于35名重复周期研究的患者，卵巢11β-HSD活性与初始周期无关。
卵巢11β-HSD活性与IVF-ET受孕失败相关。对于给定患者，卵巢11β-HSD活性在连续治疗周期之间存在差异。因此，卵巢11β-HSD活性可能在每个治疗周期中独立预测这种辅助生殖方案的结局。
